GlassScriptPhysician profile
Brett B Abernathy
NPI 1437106028
$4,643.17
in general payments reported to CMS, 2019-2025
40 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,140 · 2020: $463 · 2021: $558 · 2022: $1,105 · 2023: $1,107 · 2024: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,277 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,276.70 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $869.25 | 2019-2023 | Myrbetriq |
| Abbvie INC. | $595.00 | 2019-2024 | Botox, Lupron Depot |
| Janssen Biotech, INC. | $529.95 | 2019-2024 | Erleada, Akeega |
| Allergan, INC. | $239.02 | 2019-2022 | |
| Amgen INC. | $231.74 | 2019-2023 | Xgeva |
| Progenics Pharmaceuticals, INC. | $212.44 | 2022-2024 | Pylarify |
| Bayer Healthcare Pharmaceuticals INC. | $159.11 | 2019-2023 | |
| Karl Storz Lithotripsy-America | $152.64 | 2019 | |
| Endo Pharmaceuticals INC. | $149.51 | 2019-2023 | Xiaflex |
| Telix Pharmaceuticals | $143.91 | 2022-2023 | Illuccix |
| Sumitomo Pharma America, INC. | $97.95 | 2023-2024 | Gemtesa, Orgovyx |
| C. R. Bard, INC. & Subsidiaries | $94.43 | 2019 | |
| Urogen Pharma, INC. | $94.01 | 2022-2024 | Jelmyto |
| Myovant Sciences INC. | $87.77 | 2022 | |
| Blue Earth Diagnostics | $75.34 | 2019-2023 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Abernathy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.